Cargando…
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms
We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell responses, soluble markers of inflammation, and antibody levels and neutralization capacity longitudinally in 70 individuals with PCR-confirmed SARS-CoV-2 infection. Participants represent a spectrum of illness...
Autores principales: | Peluso, Michael J., Deitchman, Amelia N., Torres, Leonel, Iyer, Nikita S., Munter, Sadie E., Nixon, Christopher C., Donatelli, Joanna, Thanh, Cassandra, Takahashi, Saki, Hakim, Jill, Turcios, Keirstinne, Janson, Owen, Hoh, Rebecca, Tai, Viva, Hernandez, Yanel, Fehrman, Emily A., Spinelli, Matthew A., Gandhi, Monica, Trinh, Lan, Wrin, Terri, Petropoulos, Christos J., Aweeka, Francesca T., Rodriguez-Barraquer, Isabel, Kelly, J. Daniel, Martin, Jeffrey N., Deeks, Steven G., Greenhouse, Bryan, Rutishauser, Rachel L., Henrich, Timothy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s).
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342976/ https://www.ncbi.nlm.nih.gov/pubmed/34358460 http://dx.doi.org/10.1016/j.celrep.2021.109518 |
Ejemplares similares
-
Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19
por: Peluso, Michael J., et al.
Publicado: (2021) -
SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency
por: Takahashi, Saki, et al.
Publicado: (2021) -
SARS-CoV-2 Serology Across Scales: A Framework for Unbiased Estimation of Cumulative Incidence Incorporating Antibody Kinetics and Epidemic Recency
por: Takahashi, Saki, et al.
Publicado: (2023) -
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
por: Peluso, Michael J., et al.
Publicado: (2021) -
Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease
por: Peluso, Michael J, et al.
Publicado: (2021)